| Recruiting | Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patient NCT07221370 | Riverside University Health System Medical Center | Phase 2 / Phase 3 |
| Unknown | A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infectio NCT06367504 | Vedic Lifesciences Pvt. Ltd. | N/A |
| Recruiting | Study on Clostridium Difficile Infection in Infants NCT06703918 | First People's Hospital of Hangzhou | — |
| Unknown | Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection NCT04960306 | University of Pecs | Phase 3 |
| Completed | High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology NCT04940468 | University of Colorado, Denver | N/A |
| Withdrawn | Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients NCT03643887 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile NCT05192148 | Fondation Hôpital Saint-Joseph | N/A |
| Unknown | Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection NCT04885946 | Christian Hvas | N/A |
| Recruiting | Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) NCT04305769 | University of Virginia | Phase 2 |
| Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases NCT04698148 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | — |
| Unknown | Natural History of Clostridioides Difficile Infection NCT04801862 | Hospital Universitario de Valme | — |
| Completed | Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection NCT04138706 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 |
| Unknown | Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea NCT04567134 | Hanyang University Seoul Hospital | — |
| Completed | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection NCT04247542 | Acurx Pharmaceuticals Inc. | Phase 2 |
| Withdrawn | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection NCT04100603 | ProgenaBiome | — |
| Unknown | PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT NCT04259931 | Hospital Universitario de Cabuenes | — |
| Completed | Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection NCT04317963 | University of Illinois at Chicago | — |
| Completed | ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI NCT03829475 | Brigham and Women's Hospital | Phase 2 |
| Completed | The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. D NCT05703477 | Shanghai 10th People's Hospital | N/A |
| Unknown | Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm NCT04187430 | Emilio Bouza | — |
| Completed | Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using True NCT05008640 | Toi Labs, Inc. | — |
| Completed | Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With H NCT04075422 | Fundacion SEIMC-GESIDA | — |
| Terminated | Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) NCT04000555 | University of South Florida | Phase 4 |
| Terminated | Fecal Microbiota Transplant for Primary CDI NCT03795233 | Boston Medical Center | Phase 1 / Phase 2 |
| Completed | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) NCT03931941 | Rebiotix Inc. | Phase 3 |
| Terminated | Fecal Transplantation for Primary Clostridium Difficile Infection NCT03796650 | Oslo University Hospital | Phase 3 |
| Completed | Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile NCT03827447 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Safety and Efficacy of Fecal Microbiota Transplantation NCT04014413 | Chinese University of Hong Kong | N/A |
| Unknown | CDI Synbiotic Study NCT04012788 | Hvidovre University Hospital | N/A |
| Completed | FQ Restriction for the Prevention of CDI NCT03848689 | University of Wisconsin, Madison | — |
| Completed | The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation NCT03621657 | University of Wisconsin, Madison | Phase 2 |
| Completed | Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT03788434 | Vedanta Biosciences, Inc. | Phase 2 |
| Completed | Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD NCT03824795 | MGB Biopharma Limited | Phase 2 |
| Terminated | Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) NCT03005379 | VA Office of Research and Development | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) NCT03710694 | Da Volterra | N/A |
| Unknown | Fecal Microbiota Transplantation (FMT) for Clostridium Difficile NCT03712722 | University of Aarhus | — |
| Unknown | Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection NCT03586206 | Roma Tre University | — |
| Suspended | A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program NCT03350711 | Emory University | — |
| Unknown | Clostridium Difficile Virulence Mechanism Study (CDVM Study) NCT03654872 | Chinese University of Hong Kong | — |
| Completed | COMBACTE-CDI Understanding the Burden of C. Difficile Infection NCT03503474 | University of Leeds | — |
| Completed | Fecal Microbiota Transplant NCT04090346 | Methodist Health System | Phase 4 |
| Completed | Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients NCT03030248 | Medical College of Wisconsin | Phase 2 |
| Withdrawn | Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile In NCT02464306 | University of Colorado, Denver | Phase 4 |
| Completed | Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection NCT03462459 | University of Wisconsin, Madison | Phase 2 |
| Completed | Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurr NCT03497806 | Finch Research and Development LLC. | Phase 2 |
| Completed | Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) NCT03182907 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics NCT03466502 | University of Nevada, Reno | Phase 4 |
| Withdrawn | Use of Bismuth Subsalicylate in Clostridium Difficile Colitis NCT03592082 | Bassett Healthcare | Phase 4 |
| Completed | TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment NCT03388268 | Washington University School of Medicine | Phase 4 |
| Completed | MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) NCT02865616 | NuBiyota | Phase 1 |
| Recruiting | Fecal Microbiota Transplant National Registry NCT03325855 | American Gastroenterological Association | — |
| Terminated | Treatment for Clostridium-difficile Infection With IMM529 NCT03065374 | Immuron Ltd. | Phase 1 / Phase 2 |
| Unknown | Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS NCT03141775 | University of Cologne | — |
| Completed | The ICON Study: Outcomes After FMT for Patients With IBD and CDI NCT03106844 | Brigham and Women's Hospital | Phase 1 / Phase 2 |
| Completed | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection NCT03183128 | Seres Therapeutics, Inc. | Phase 3 |
| Completed | Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection NCT03349268 | University of Michigan | N/A |
| Terminated | Oral Vancomycin for Preventing Clostridium Difficile Recurrence NCT03200093 | Rochester General Hospital | Phase 4 |
| Terminated | Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) NCT03105479 | Actelion | Phase 2 / Phase 3 |
| Completed | Clostridium Difficile Vaccine Efficacy Trial NCT03090191 | Pfizer | Phase 3 |
| Completed | Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Diffici NCT02968758 | Meridian Bioscience, Inc. | N/A |
| Unknown | A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile NCT03053505 | Sejtterapia Kozpont Kft. | N/A |
| Terminated | Oral Vaccination Against Clostridium Difficile Infection NCT02991417 | Simon M. Cutting | Phase 1 |
| Completed | Screening to Prophylax Against Clostridium Difficile Infection - NCT02996487 | Corewell Health East | Phase 4 |
| Unknown | Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection NCT02686645 | Queen Elizabeth II Health Sciences Centre | Phase 2 / Phase 3 |
| Unknown | Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection NCT03804736 | Universidad Autonoma de Nuevo Leon | N/A |
| Completed | Treatment of Recurrent Clostridium Difficile Infection With RBX7455 NCT02981316 | Mayo Clinic | Phase 1 |
| Completed | Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibio NCT02951702 | St. Luke's Hospital, Chesterfield, Missouri | Phase 4 |
| Completed | Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium D NCT03250104 | University Hospital of Cologne | — |
| Completed | SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence NCT02830542 | Seres Therapeutics, Inc. | Phase 1 |
| Completed | Protocol for Admission Toxigenic C. Difficile Surveillance NCT04014608 | Endeavor Health | — |
| Completed | Specific Carbohydrate Diet for Clostridium Difficile NCT03925636 | David Suskind | N/A |
| Completed | Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection NCT02743234 | University of Aarhus | Phase 3 |
| Terminated | Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir NCT02707198 | St. Luke's Hospital of Duluth | Phase 2 |
| Completed | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection NCT02589847 | Rebiotix Inc. | Phase 2 |
| Terminated | Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection NCT02395848 | McMaster University | Phase 3 |
| Unknown | Gut Microbiota Changes After Fecal Microbiota Transplantation NCT02557685 | The Miriam Hospital | Phase 2 |
| Completed | Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile NCT03025672 | Lille Catholic University | — |
| Terminated | Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection NCT02053350 | University of Virginia | Phase 2 |
| Unknown | Freeze-dried, Capsulized FMT for RCDI NCT02399618 | Jinling Hospital, China | Phase 1 |
| Terminated | IMT for Primary Clostridium Difficile Infection NCT02301000 | Oslo University Hospital | Phase 2 / Phase 3 |
| Completed | Treatment of Initial Clostridium Difficile Infection NCT03107169 | Universidad Autonoma de Nuevo Leon | N/A |
| Terminated | FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI NCT02255305 | Endeavor Health | Phase 2 |
| Completed | Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile? NCT02461901 | Professor Mark Wilcox | — |
| Unknown | FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment NCT02570477 | Chinese University of Hong Kong | N/A |
| Completed | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infect NCT02784002 | Summit Therapeutics | Phase 2 |
| Terminated | Effect of Acid Suppression Medication on Pediatric Microbiome NCT02016820 | Columbia University | N/A |
| Completed | Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection NCT02214771 | Astellas Pharma S.A.S. | — |
| Unknown | Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection NCT02237859 | Corewell Health West | Phase 4 |
| Completed | Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. NCT02106338 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection NCT02326636 | University of California, Irvine | — |
| Completed | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea ( NCT02092935 | Summit Therapeutics | Phase 2 |
| Completed | Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhe NCT01987895 | Actelion | Phase 3 |
| Completed | Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries NCT02223715 | Otsuka Pharmaceutical Co., Ltd. | — |
| Recruiting | Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium D NCT03562741 | Krunal Patel | N/A |
| Completed | Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea NCT01983683 | Actelion | Phase 3 |
| Completed | Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis NCT03268213 | Stony Brook University | EARLY_Phase 1 |
| Unknown | Transplantation of Fecal Microbiota for Clostridium Difficile Infection NCT01958463 | Tel-Aviv Sourasky Medical Center | Phase 3 |
| Terminated | Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Dia NCT01972932 | Bio-K Plus International Inc. | Phase 4 |
| Unknown | Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis NCT01942447 | University Hospital Tuebingen | N/A |
| Withdrawn | Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT) NCT01842347 | Medical College of Wisconsin | N/A |
| Completed | Pathogenic Mechanisms in C Diff Infection and Colitis NCT01930032 | Beth Israel Deaconess Medical Center | — |
| Completed | Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Froze NCT01914731 | Massachusetts General Hospital | Phase 1 |
| Terminated | Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection NCT01887912 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Recruiting | Fecal Microbiota Transplantation for C Diff Infection NCT01905709 | Englewood Hospital and Medical Center | N/A |
| Completed | Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Jap NCT01896830 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | The Impact of Proton Pump Inhibitors on the Fecal Microbiome NCT01822977 | Mayo Clinic | Phase 1 |
| Completed | Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections NCT01946750 | Versailles Hospital | N/A |
| Completed | Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea NCT01670149 | University of Nottingham | Phase 4 |
| Completed | Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen I NCT01704937 | Massachusetts General Hospital | Phase 1 |
| Completed | Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Va NCT01818141 | Hartford Hospital | Phase 4 |
| Withdrawn | Fidaxomicin to Prevent Clostridium Difficile Colonization NCT01552668 | Washington University School of Medicine | Phase 4 |
| Completed | Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infec NCT02053181 | Actelion | Phase 1 |
| Completed | Multi-Centre Trial of Fresh vs. Frozen-and-Thawed FMT for Recurrent CDI NCT01398969 | McMaster University | Phase 2 |
| Completed | A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) NCT01598311 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) NCT01597505 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infecti NCT01513239 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific NCT01560832 | Yonsei University | — |
| Completed | A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Diffici NCT01241552 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection NCT02086916 | Barts & The London NHS Trust | — |
| Completed | Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection NCT01259726 | Shire | Phase 2 |
| Completed | Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related In NCT01295918 | St Marina University Hospital, Varna, Bulgaria | Phase 3 |
| Completed | Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDA NCT01222702 | Actelion | Phase 2 |
| Completed | An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 NCT01296386 | Valneva Austria GmbH | Phase 1 |
| Completed | Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules i NCT01230957 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of CB-183,315 in Participants With Clostridium Difficile Infection NCT01085591 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Withdrawn | Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infecti NCT01077245 | Osel, Inc. | Phase 2 |
| Completed | Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study NCT02327520 | King Chulalongkorn Memorial Hospital | — |
| Terminated | Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection NCT01372943 | Queen's University | N/A |
| Completed | Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection NCT00772343 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial NCT00563186 | University of Calgary | N/A |
| Terminated | Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenic NCT00772954 | Sanofi | Phase 1 |